Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

Mohamed A Kharfan-Dabaja; Ambuj Kumar; Ernesto Ayala; Mehdi Hamadani; Peter Reimer; Christian Gisselbrecht; Francesco d'Amore; Esa Jantunen; Takashi Ishida; Ali Bazarbachi; Francine Foss; Ranjana Advani; Timothy S Fenske; Hillard M Lazarus; Jonathan W Friedberg; Mahmoud Aljurf; Lubomir Sokol; Kensei Tobinai; Eric Tse; Linda J Burns; Julio C Chavez; Nishitha M Reddy; Ritsuro Suzuki; Sairah Ahmed; Auayporn Nademanee; Mohamad Mohty; Ajay K Gopal; Michelle A Fanale; Barbara Pro; Alison J Moskowitz; Anna Sureda; Miguel Angel Perales; Paul A Carpenter; Bipin N Savani

doi:10.1016/j.bbmt.2017.07.027

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

Biol Blood Marrow Transplant. 2017 Nov;23(11):1826-1838. doi: 10.1016/j.bbmt.2017.07.027. Epub 2017 Aug 7.

Authors

Mohamed A Kharfan-Dabaja¹, Ambuj Kumar², Ernesto Ayala³, Mehdi Hamadani⁴, Peter Reimer⁵, Christian Gisselbrecht⁶, Francesco d'Amore⁷, Esa Jantunen⁸, Takashi Ishida⁹, Ali Bazarbachi¹⁰, Francine Foss¹¹, Ranjana Advani¹², Timothy S Fenske⁴, Hillard M Lazarus¹³, Jonathan W Friedberg¹⁴, Mahmoud Aljurf¹⁵, Lubomir Sokol¹⁶, Kensei Tobinai¹⁷, Eric Tse¹⁸, Linda J Burns¹⁹, Julio C Chavez¹⁶, Nishitha M Reddy²⁰, Ritsuro Suzuki²¹, Sairah Ahmed²², Auayporn Nademanee²³, Mohamad Mohty²⁴, Ajay K Gopal²⁵, Michelle A Fanale²², Barbara Pro²⁶, Alison J Moskowitz²⁷, Anna Sureda²⁸, Miguel Angel Perales²⁷, Paul A Carpenter²⁵, Bipin N Savani²⁰

Affiliations

¹ Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute and Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, Florida. Electronic address: mohamed.kharfan-dabaja@moffitt.org.
² Program for Comparative Effectiveness Research, Morsani College of Medicine, University of South Florida, Tampa, Florida.
³ Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute and Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, Florida.
⁴ Department of Internal Medicine, Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
⁵ Department of Hematology, Medical Oncology and Stem Cell Transplantation, Evangelisches Krankenhaus Essen-Werden, Essen, Germany.
⁶ Institute of Hematology, Saint Louis Hospital, Paris, France.
⁷ Dept of Hematology, Aarhus University Hospital, Aarhus, Denmark.
⁸ Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
⁹ Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
¹⁰ Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
¹¹ Yale University School of Medicine, New Haven, Connecticut.
¹² Stanford University, Palo Alto, California.
¹³ Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.
¹⁴ James P. Wilmot Cancer Institute, University of Rochester, Rochester, New York.
¹⁵ Oncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
¹⁶ Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute and Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida Tampa, Florida.
¹⁷ Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
¹⁸ Department of Medicine, The University of Hong Kong, Hong Kong.
¹⁹ National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.
²⁰ Vanderbilt University Medical Center, Nashville, Tennessee.
²¹ Department of Oncology/Hematology, Shimane University Hospital, Shimane, Japan.
²² University of Texas M.D. Anderson Cancer Center, Houston, Texas.
²³ Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
²⁴ Saint-Antoine Hospital, Pierre and Marie Curie University, INSERM UMRs U938, Paris, France.
²⁵ Fred Hutchinson Cancer Research Center, Seattle, Washington.
²⁶ Northwestern University, Chicago, Illinois.
²⁷ Memorial Sloan Kettering Cancer Center, New York, New York.
²⁸ Clinical Hematology Department, Institut Català d'Oncologia, Barcelona, Spain.

PMID: 28797780
DOI: 10.1016/j.bbmt.2017.07.027

Abstract

Recognizing the significant biological and clinical heterogeneity of mature T cell and natural killer (NK)/T cell lymphomas, the American Society for Blood and Marrow Transplantation invited experts to develop clinical practice recommendations related to the role of autologous hematopoietic cell transplantation (auto-HCT) and allogeneic HCT (allo-HCT) for specific histological subtypes. We used the GRADE methodology to aid in moving from evidence to decision making and ultimately to generating final recommendations. Auto-HCT in front-line consolidation is recommended in peripheral T cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), anaplastic large cell lymphoma-anaplastic lymphoma kinase (ALCL-ALK)-negative, NK/T cell (disseminated), enteropathy-associated T cell lymphoma (EATL), and hepatosplenic lymphomas. Auto-HCT in relapsed-sensitive disease is recommended for NK/T cell (localized and disseminated), EATL, subcutaneous panniculitis-like T cell, and ALCL-ALK-positive lymphomas. Auto-HCT is also recommended for PTCL-NOS, AITL, and ALCL-ALK-negative lymphomas if not performed as front-line therapy. Auto-HCT in refractory (primary or relapsed) disease is not recommended for any of the histological subtypes discussed. Allo-HCT in front-line consolidation is recommended for NK/T cell (disseminated), adult T cell leukemia/lymphoma (ATLL; acute and lymphoma type), and hepatosplenic lymphomas. Allo-HCT for relapsed-sensitive disease is recommended for PTCL-NOS, AITL, ALCL-ALK-negative, ALCL-ALK-positive, NK/T cell (localized and disseminated), ATLL (acute, lymphoma type, smoldering/chronic), mycosis fungoides/Sezary syndrome (advanced stage IIB-IVB or tumor stage/extracutaneous), EATL, subcutaneous panniculitis-like T cell, and hepatosplenic lymphoma. Allo-HCT in refractory (primary or relapsed refractory) disease is recommended for any aforementioned histological subtypes. Emerging novel therapies will likely be incorporated into the pretransplantation, peritransplantation, and post-transplantation algorithms (auto-HCT or allo-HCT) with the goals of optimizing efficacy and improving outcomes. We acknowledge that there are unique clinical scenarios not covered by these recommendations that may require individualized decisions.

Keywords: Allogeneic hematopoietic cell transplantation; Autologous hematopoietic cell transplantation; NK/T cell lymphomas; T cell lymphomas.

MeSH terms

Adult
Aged
Guidelines as Topic
Hematopoietic Stem Cell Transplantation / methods*
Humans
Lymphoma, T-Cell, Peripheral / therapy*
Middle Aged
T-Lymphocytes / metabolism*
United States